Takeda's First Female CEO Leverages AI to Reshape Biopharma Business Landscape
AI News Flash: Takeda Pharmaceutical Co. officially welcomed its first female CEO, Julie Kim, on June 25, 2026. In her media interview, she stated she would continue the structural reforms driven by her predecessor Christophe Weber, and further deepen AI applications to achieve a more lean and efficient enterprise management model. Julie Kim’s appointment itself carries symbolic significance, marking her as the first female leader in this Japanese pharmaceutical giant’s century-long history. She emphasized that Takeda will continue investing in innovative drug R&D to maintain its competitive position in the global biopharma sector. However, the publicly available reports have not yet revealed specific AI applications in business processes, projected investment scale, or quantified targets, nor have they provided further details on the implementation specifics of the structural reforms. For the full story, see the original link.